Brokerages Set Genelux Co. (NASDAQ:GNLX) Price Target at $17.75

Shares of Genelux Co. (NASDAQ:GNLX) have earned an average recommendation of “Buy” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $17.75.

GNLX has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Genelux in a research report on Monday, March 31st. Benchmark dropped their price target on Genelux from $25.00 to $23.00 and set a “speculative buy” rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen raised Genelux from a “sell” rating to a “hold” rating in a research report on Saturday.

Genelux Price Performance

NASDAQ GNLX opened at $3.06 on Friday. The firm has a market cap of $115.47 million, a P/E ratio of -3.22 and a beta of -0.49. The stock’s 50-day moving average is $2.59 and its 200-day moving average is $3.07. Genelux has a one year low of $1.60 and a one year high of $5.89.

Genelux (NASDAQ:GNLX) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Equities analysts anticipate that Genelux will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GNLX. Apollon Wealth Management LLC grew its holdings in shares of Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after buying an additional 2,857 shares in the last quarter. D.A. Davidson & CO. bought a new position in shares of Genelux during the fourth quarter worth about $51,000. LifeSteps Financial Inc. grew its holdings in shares of Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after buying an additional 8,715 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Genelux during the fourth quarter worth about $41,000. Finally, Virtu Financial LLC bought a new position in shares of Genelux during the fourth quarter worth about $25,000. 37.33% of the stock is currently owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.